Aurinia Pharmaceuticals (AUPH) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
UroGen Pharma (URGN) has outperformed Aurinia Pharmaceuticals (AUPH) over the past year, gaining 113.4% versus a gain of 40.7%. Over five years, URGN leads with a +117.3% price change compared with -21.1% for AUPH. Aurinia Pharmaceuticals is the larger company by market cap ($2.17 billion vs $1.83 billion), about 1.2 times the size, while UroGen Pharma is growing revenue faster (+21.4% vs +20.4%).
On valuation, UroGen Pharma trades at a lower forward P/E (13.4x vs 15.3x for Aurinia Pharmaceuticals). Aurinia Pharmaceuticals converts more of its revenue into profit, with a net margin of 101.5% versus -139.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | URGN |
|---|---|---|
| Share price | $16.30 | $37.47 |
| Market cap | $2.17B | $1.83B |
| 1-day change | +0.49% | +1.31% |
| YTD return | +1.69% | +57.90% |
| 1-year return | +40.68% | +113.39% |
| 5-year return | -21.15% | +117.27% |
| P/E ratio (TTM) | 7.15 | — |
| Forward P/E | 15.28 | 13.41 |
| EPS (TTM) | $2.28 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $283.06M | $109.79M |
| Revenue growth (YoY) | +20.38% | +21.45% |
| Net income (latest FY) | $287.20M | $-153.49M |
| Gross margin | 88.46% | 88.66% |
| Operating margin | 37.06% | -113.73% |
| Net margin | 101.47% | -139.81% |
| 52-week high | $19.25 | $50.81 |
| 52-week low | $10.90 | $15.86 |
| Distance from 52-week high | -15.32% | -26.26% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +9.57% | +60.15% |
| Average volume | 977.05K | 849.01K |
| Shares outstanding | 133.05M | 48.88M |
| Employees | 128 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed AUPH by 72.7 percentage points over the past year.
- Aurinia Pharmaceuticals is more profitable, keeping 101.5 cents of every revenue dollar as net income versus -139.8 cents for UroGen Pharma.
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
AUPH vs URGN FAQ
Which is bigger, Aurinia Pharmaceuticals or UroGen Pharma?
Aurinia Pharmaceuticals (AUPH) is larger, with a market capitalization of $2.17B compared with $1.83B for UroGen Pharma (URGN).
Which stock has performed better over the past year, AUPH or URGN?
URGN returned +113.39% over the past 12 months, compared with +40.68% for AUPH (price return, excluding dividends). Past performance does not predict future results.
Are Aurinia Pharmaceuticals and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.